Dr. Philip Sager, FACC, FAHA, FHRS

Director

Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society. Dr. Sager has served as a Consulting Professor of Medicine at the Stanford University School of Medicine since 2013, a Full Voting Member of the United States Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee since 2011 (and the Committee Chair since 2015), a private pharmaceutical, device and diagnostics consultant since 2010 and Member of the Executive Committee of the Cardiac Safety Research Consortium since 2006, serving as Chair of the Scientific Programs Committee and Scientific Oversight Committee at various times. From 2009 through 2010 Dr. Sager was Vice President, Clinical Research and Head, CV/Metabolic Development for Gilead Sciences, a biotechnology company

Dr. Sager holds an M.D. from Yale University School of Medicine and B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology.